Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

The targeted agent, surufatinib, is a tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptor (VEGFR ... demonstrated an inimitable spatial structure, high programmed ...

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) ...

UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

The Feinstein Institutes for Medical Research has selected Jeffery W. Kelly, PhD, from Scripps Research, to receive the 12th annual Ross Prize in Molecular Medicine. Dr. Kelly is recognized for his ...

Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein ... They found that early pathological forms of α-synuclein, known as oligomers, activated the Toll-like receptor ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. And welcome to Invivyd’s First Quarter ...

Sensei Biotherapeutics reports promising clinical data in PD-(L)1-resistant cancer patients, with cash to fund operations through Q2 2026. Sensei Biotherapeutics, Inc. announced promising clinical ...

A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory ...